 | |
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C17H20ClN5O3 |
| Molar mass | 377.83 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Dasolampanel (INN,USAN, code nameNGX-426) is anorally bioavailableanalog oftezampanel and therebycompetitive antagonist of theAMPA andkainate receptors which was under development byRaptor Pharmaceuticals/Torrey Pines Therapeutics for the treatment ofchronic pain conditions includingneuropathic pain andmigraine.[1] It was developed as a follow-on compound to tezampanel, as tezampanel is not bioavailable orally and must be administered byintravenous injection,[2][3] but ultimately neither drug was ever marketed.
